AgenT-797

SystImmune will present updated safety and efficacy data for izalontamab brengitecan (iza-bren), an EGFRxHER3 bispecific antibody-drug conjugate, in locally advanced or metastatic breast cancer at ESMO Breast 2025 on May 16.

ARCALYST achieved remarkable growth with $417 million in 2024 net product revenue, representing a 79% year-over-year increase, with projected 2025 revenue between $560-580 million.

Agenus will showcase interim data from a Phase 2 study combining BOT/BAL with iNKT cell therapy AgenT-797 in refractory gastric cancer patients at the AACR IO Annual Meeting.

MiNK Therapeutics' agenT-797, combined with botensilimab and balstilimab, demonstrates robust immune activation in refractory gastroesophageal cancer.

A new Phase II study is investigating the combination of agenT-797, an innovative iNKT cell therapy, with botensilimab, an Fc-enhanced anti-CTLA-4 inhibitor, in gastroesophageal cancer. This trial addresses a critical need in a disease that causes 1.3 million deaths annually, targeting patients who have progressed after standard treatments.